Pharmacology of 5-aza-2′-deoxycytidine (decitabine)

Seminars in Hematology

Volumn 42, Issue SUPPL. 2, 2005, Pages

  Momparler, Richard L ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CYTARABINE; CYTIDINE DEAMINASE; DEOXYCYTIDINE KINASE; VALPROIC ACID; ZEBULARINE;

ACUTE GRANULOCYTIC LEUKEMIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL LOSS; CHROMOSOME ABERRATION; CLINICAL TRIAL; CLONOGENESIS; CONCENTRATION RESPONSE; DNA METHYLATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INFORMATION; DRUG METABOLISM; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVITY; EPIGENETICS; GENE SILENCING; HUMAN; LEUKEMIA; LEUKOPENIA; MYELODYSPLASTIC SYNDROME; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA;

EID: 21844466446     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2005.05.002     Document Type: Article

References (67)

1. S.A. Belinsky, D.M. Klinge, C.A. Stidley Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer Cancer Res 63 2003 7089 7093
2. J. Bouchard, R.L. Momparler Incorporation of 5-aza-2′- deoxycytidine-5′-triphosphate into DNA. Interactions with DNA polymerase and DNA methylase Mol Pharmacol 24 1983 109 114
3. D.Y. Bouffard, L.F. Momparler, R.L. Momparler Enhancement of the antileukemic activity of 5-aza-2′-deoxycytidine by cyclopentenyl cytosine in HL-60 leukemic cell line Anticancer Drugs 5 1994 223 228
4. W.R. Bruce, B.E. Meeker, W.E. Powers Comparison of the dose- and time survival curves for normal and lymphoma colony-forming cells exposed to vinblastine, vincristine, arabinofuranosycytosine, and amphotericin J Natl Cancer Inst 42 1969 1015 1025
5. E.E. Cameron, K.E. Bachman, S. Myöhänen Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer Nature Genet 21 1999 103 107
6. B.I. Carr, S. Rahbar, Y. Aseron Carcinogenicity and haemoglobin synthesis induction by cytidine analogues Br J Cancer 57 1988 395 402
7. G. Chabot, J. Bouchard, R.L. Momparler Kinetics of deamination of 5-aza-2′-deoxycytidine and cytosine arabinoside by human liver cytidine deaminase and its inhibition by 3-deazauridine, thymidine or uracil arabinoside Biochem Pharmacol 32 1983 1327 1328
8. G. Chabot, R.L. Momparler Plasma and cerebral spinal fluid pharmacokinetics of 5-aza-2′-deoxycytidine in rabbits and dogs Cancer Res 43 1983 592 597
9. N. Eliolopoulos, R.L. Momparler Drug resistance to 5′-aza-2′- deoxycytidine, 2,2′-difluorodeoxycytidine and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells Cancer Chemother Pharmacol 42 1998 373 378
10. N.J. Farinha, S. Shaker, M. Lemaire Activation of expression of p15, p73 and E-cadherin by different concentrations of 5-aza-2′-deoxycytidine Anticancer Res 24 2004 75 78
11. F. Gaudet, J.G. Hodgson, A. Aden Induction of tumors in mice by genomic hypomethylation Science 300 2003 489 492
12. J.P. Issa Decitabine Curr Opin Oncol 15 2003 446 451
13. J.P. Issa, G. Garcia-Manero, F.J. Giles Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′- deoxycytidine (decitabine) in hematopoietic malignancies Blood 103 2004 1635 1640
14. L. Jackson-Grusby, P.W. Laird, S.N. Magge Mutagenicity of 5-aza-2′-deoxycytidine is mediated by the mammalian DNA methyltransferase Proc Natl Acad Sci U S A 94 1997 4681 4685
15. W. Ji, R. Henandez, X.-Y. Zhang DNA demethylation and pericentromeric rearrangements of chromosome 1 Mutation Res 379 1997 33 41
16. P.A. Jones, S.B. Baylin The fundamental role of epigenetic events in cancer Nature Rev Genet 3 2002 415 428
17. P.A. Jones, S.M. Taylor Cellular differentiation, cytidine analogs and DNA methylation Cell 20 1980 85 93
18. R. Juttermann, E. Li, R. Jaenisch Toxicity of 5-aza-2′- deoxycytidine to mammalian cells is mediated by covalent trapping of DNA methyltransferase rather than DNA demethylation Proc Natl Acad Sci U S A 91 1994 11797 11801
19. H.M. Kantarjian, S.M. O'Brien, M. Keating Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia Leukemia 11 1997 1617 1620
20. P.W. Laird, L. Jackson-Grusby, A. Fazeli Suppression of intestinal neoplasms by DNA hypomethylation Cell 81 1995 197 205
21. J.R. Landolph, P.A. Jones Mutagenicity of 5-azacytidine and related nucleosides in C3H/10T1/2 clone 8 and V79 cells Cancer Res 42 1982 817 820
22. J. Laliberté, V.E. Marquez, R.L. Momparler Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2′-deoxycytidine by human cytidine deaminase Cancer Chemother Pharmacol 30 1992 7 11
23. D.E. Laux, F. Rahmatpanah, O. Sjahputera Genomic DNA methylation profiles of the granulocytic subtypes of acute myelogenous leukemia Proc Am Assoc Cancer Res 46 2005 204 (abstr)
24. M. Lemaire, L.F. Momparler, M. Bernstein Enhancement of antineoplastic action of 5-aza-2′-deoxycytidine by zebularine on L1210 leukemia Anticancer Drugs 16 2005 301 308
25. M. Lemaire, L.F. Momparler, N.J. Farinha Enhancement of antineoplastic activity of 5-aza-2′-deoxycytidine by phenylbutyrate on L1210 leukemic cells Leuk Lymphoma 45 2004 147 154
26. K.-T. Lin, R.L. Momparler, G.E. Rivard High-performance liquid chromatographic analysis of chemical stability of 5-aza-2′-deoxycytidine J Pharmaceut Sci 70 1981 1228 1232
27. E. Li Chromatin modification and epigenetic programming in mammalian development Nature Rev Genet 3 2002 662 673
28. M. Lübbert, P. Wijermans, R. Kunzmann Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine Br J Haematol 114 2001 349 357
29. R.L. Momparler Effect of cytosine arabinoside 5′-triphosphate on mammalian DNA polymerase Biochem Biophys Res Commun 34 1968 465 471
30. R.L. Momparler Model for the chemotherapy of acute leukemia with 1-β-arabinofuranosylcytosine Cancer Res 34 1974 1775 1787
31. R.L. Momparler Molecular, cellular and animal pharmacology of 5-aza-2-deoxycytidine Pharmacol Ther 30 1986 287 299
32. R.L. Momparler, J. Bouchard, N. Onetto 5-Aza-2′-deoxycytidine therapy in patients with acute leukemia inhibits DNA methylation Leuk Res 8 1984 181 185
33. R.L. Momparler, D.Y. Bouffard, L.F. Momparler Pilot phase I-II study on 5-aza-2′-deoxycytidine (decitabine) in patients with metastatic lung cancer Anticancer Drugs 8 1997 358 368
34. R.L. Momparler, M.Y. Chu, G.A. Fischer Studies on a new mechanism of resistance of L5178Y murine leukemic cells to cytosine arabinoside Biochem Biophys Acta 161 1968 481 493
35. R.L. Momparler, S. Cǒté, N. Eliopoulos Pharmacological approach for optimization of the dose-schedule of 5-aza-2′-deoxycytidine (decitabine) for the therapy of leukemia Leukemia 11 1997 175 180
36. R.L. Momparler, D. Derse Kinetics of phosphorylation of 5-aza-2′-deoxycytidine by deoxycytidine kinase Biochem Pharmacol 28 1979 1443 1444
37. R.L. Momparler, C.H. Frith Toxicology in mice of the antileukemic agent 5-aza-2′-deoxycytidine Drug Chem Toxicol 4 1981 373 381
38. R.L. Momparler, F.A. Gonzales Effect of intravenous infusions of 5-aza-2′-deoxycytidine on survival time of mice with L1210 leukemia Cancer Res 38 1978 2673 2678
39. R.L. Momparler, F.A. Gonzales, L.F. Momparler Preclinical evaluation of hematopoietic toxicity of antileukemic agent, 5-aza-2′-deoxycytidine Toxicology 57 1989 329 336
40. R.L. Momparler, L.F. Momparler Chemotherapy of L1210 and L1210/ARA-C leukemia with 5-aza-2′-deoxycytidine and 3-deazauridine Cancer Chemother Phamacol 25 1980 51 54
41. R.L. Momparler, R.L. Momparler, J. Samson Comparison of the antileukemic activity of 5-aza-2′-deoxycytidine, 1-β-D-arabinofuranosylcytosine and 5-azacytidine against L1210 leukemia Leuk Res 8 1984 1043 1049
42. R.L. Momparler, N. Onetto-Pothier, L.F. Momparler Comparison of antineoplastic activity of cytosine arabinoside and 5-aza-2′-deoxycytidine against human leukemic cells of different phenotype Leuk Res 14 1990 755 760
43. R.L. Momparler, G.E. Rivard, M. Gyger Clinical trial on 5-aza-2-deoxycytidine in patients with acute leukemia Pharmacol Ther 30 1986 277 286
44. R.L. Momparler, M. Rossi, J. Bouchard Kinetic interaction of 5-aza-2′-deoxycytidine 5′-monophosphate and its 5′- triphosphate with deoxycytidine deaminase Mol Pharmacol 25 1984 436 440
45. R.L. Momparler, J. Samson, L.F. Momparler Cell cycle effects and cellular pharmacology of 5-aza-2′-deoxycytidine Cancer Chemother Pharmacol 13 1984 191 194
46. R.L. Momparler, J. Vesely, L.F. Momparler Synergistic action of 5-aza-2′-deoxycytidine and 3-deazauridine on L1210 leukemic cells and EMT tumor cells Cancer Res 39 1979 3822 3827
47. N. Onetto, R.L. Momparler, L.F. Momparler In vitro tests to evaluate the response to therapy of acute leukemia with cytosine arabinoside or 5-aza-deoxycytidine Semin Oncol 14 1987 231 237
48. A. Pinto, V. Attadia, A. Fusco 5-Aza-2′-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias Blood 64 1984 922 929
49. A. Pinto, V. Zagonel 5-Aza-2′-deoxycytidine (decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndrome Past, present and future trends Leukemia 7 suppl 1 1993 51 60
50. J. Pliml, F. Sorm Synthesis of a deoxy-D-ribofuranosyl-5-cytosine Collection Czech Chem Commun 29 1964 2576 2577
51. D.J. Richel, L.P. Colly, J.C. Kluin-Nelemans The antileukaemic activity of 5-aza-2 deoxycytidine (Aza-dC) in patients with relapsed and resistant leukaemia Br J Cancer 64 1991 144 149
52. G.E. Rivard, R.L. Momparler, J. Demers Phase I study on 5-aza-2′-deoxycytidine in children with acute leukemia Leuk Res 5 1981 453 462
53. B. Sanchez-Gonzales, H. Yang, M. Cuadros In vitro molecular implications of the combination of the hypomethylating agent 5-aza-2′-deoxycytidine and the histone deacetylase inhibitor valproic acid in patients with leukemia. Results of phase I/II study Proc Am Assoc Cancer Res 46 2005 937 (abstr)
54. S. Shaker, M. Bernstein, R.L. Momparler Antineoplastic action of 5-aza-2′- deoxycytidine (Dacogen) and depsipeptide on Raji lymphoma cells Oncol Rep 11 2004 1253 1256
55. S. Shaker, M. Bernstein, L.F. Momparler Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2′- deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) against myeloid leukemic cells Leuk Res 27 2003 437 444
56. L. Sigalotti, S. Corsi, G. Nardi Promoter methylation controls the expression of MAGE 2, 3 and 4 genes in human cutaneous melanoma J Immunother 25 2002 16 26
57. H.E. Skipper, F.M. Shabel, W.S. Willcox Experimental evaluation of potential anticancer agents. XXI. Scheduling of arabinosylcytosine to take advantage of its S phase specificity Cancer Chemother Rep 51 1967 125 165
58. F. Sorm, J. Vesely Effect of 5-aza-2-deoxycytidine against leukemic and hemopoietic tissues in AKR mice Neoplasma 15 1968 339 343
59. R. Stasi, A. Venditti, G. Del Poeta High-dose chemotherapy in adult myeloid leukemia Rationale and results Leuk Res 20 1996 535 549
60. R.D. Snyder, P.J. Lachmann Differential effects of 5-azacytidine and 5-azadeoxycytidine on cytotoxicity, DNA-strand breaks and repair of X-ray induced DNA damage in HeLa cells Mutation Res 226 1989 185 190
61. J. Weber, M. Salgaller, D. Samid Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2 deoxycytidine Cancer Res 54 1994 1766 1771
62. J.K. Weick, K.J. Kepecky, F.R. Appelbaum A randomized investigation of high dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia A Southwest Oncology Group study Blood 88 1996 2841 2851
63. J.S. Wiley, S.P. Jones, W.H. Sawyer Cytosine arabinoside influx and nucleoside transport sites in acute leukemia J Clin Invest 69 1982 479 489
64. V.L. Wilson, P.A. Jones, R.L. Momparler Inhibition of DNA methylation in L1210 leukemic cells by 5-aza-2′-deoxycytidine as a possible mechanism for chemotherapeutic action Cancer Res 43 1983 349 3497
65. A.S. Yang, M.R.H. Estecio, G. Garcia-Manero Comment on "Chromosome instability and tumors promoted by DNA hypomethylation" and "Induction of tumors in mice by genomic hypomethylation." Science 302 2003 1153
66. C.B. Yoo, J.C. Cheng, P.A. Jones Zebularine A new drug for epigenetic therapy Biochem Soc Trans 32 2004 910 912
67. V. Zagonel, G. Lo Re, G. Marotta 5-Aza-2′-deoxycytidine (decitabine) induces trilineage response in unfavorable myelodysplastic syndromes Leukemia 7 suppl 1 1993 30 35